1 Endothelin-l binds almost irreversibly to its receptors and causes prolonged vasoconstrictions. Here we have studied the reversal of established responses to ET-l in vivo and in vitro by BQ-123, an ETA receptor-selective antagonist, and/or PD 145065, an ETA/ETB receptor non-selective antagonist. 2 In anaesthetized rats pretreated with hexamethonium, infusion of ET-1 (10-" mol kg-' min-) increased the mean arterial pressure (MAP) from 93 ± 1.5 mmHg to 137 ± 2.4 mmHg after 70 min (n = 29). While the ET-1 infusion was continued an additional infusion of BQ-123 caused a gradual dose-dependent reduction in the pressor effect of ET-1. For instance, after a 60 min infusion of BQ-123 (10-8mol kg-' min-') the MAP was decreased by 29.3 ± 4.3 mmHg (n = 4). 3 PD 145065 was a much weaker antagonist of the established pressor effects of ET-1. At 10-8mol kg-' min-' it had no significant effect and even at 10-mol kg-' min' the elevated blood pressure was only reduced by 11.8 ± 8.0 mmHg (n = 5) after 60 min. Co-infusion of BQ-123 and PD 145065 caused smaller reductions in the established response to ET-1 than infusion of BQ-123 alone. 4 Sustained contractions of rat aortic rings induced by ET-1 (3 x 10-9 M) and mediated by ETA receptors were slowly reversed by addition of BQ-123 (10-s M) or PD 145065 (10-5 M). For instance, after 40 min the elevated tone was reduced 85.8 ± 5.6% (n = 6) by PD 145065, and 77.1 ± 6.7% (n = 6) by BQ-123. Thus, on the rat aortic rings in vitro both antagonists were equally effective against established responses to ET-1. 5 ET-1 increased the perfusion pressure of the rat isolated perfused kidney by 138.1 ± 7.6 mmHg (n = 14). Subsequent co-infusion of BQ-123 or PD 145065 reversed this increase with PD 145065 being more active. For instance, PD 145065 (10-6 M) reversed the increase in perfusion pressure by 56.9 + 8.8% (n = 5) and BQ-123 (10-6 M) reversed it by 22.8 ± 8.0% (n = 5). This fits well with the vasoconstriction induced by ET-1 in the rat kidney being mediated by ETA and ETB receptors. 6 Thus, sustained vasoconstrictions to ET-1 in vitro, mediated by either ETA or ETB receptors, may be reversed slowly by the subsequent application of receptor antagonists. Similarly, endothelin antagonists reverse the pressor effects of ET-1 in vivo although co-antagonism of ETA and ETB receptors or the co-administration of an ETA receptor antagonist, BQ-123, and a mixed antagonist, PD 145065 produces less reversal than the application of an ETA receptor-selective antagonist. This may be because PD 145065 also reduces vasodilatations induced by ET-1 in vivo, or could suggest that because of its peptide structure PD 145065 affects the elimination of ET-1.
Introduction
The endothelins (endothelin-1, ET-1; ET-2; ET-3) are a family of structurally related peptides (Inoue et al., 1989) . Their effects are mediated by at least two receptors; the ETA receptor that has several hundred fold more affinity for ET-1 or ET-2 than ET-3, and the ETB receptor that accepts the endothelins with equal affinity (Arai et al., 1990; Sakurai et al., 1990) . Either receptor may mediate constrictions to in both vascular and non-vascular smooth muscle (Clozel et al., 1992; Harrison et al., 1992; Hay, 1992; Moreland et al., 1992; Sumner et al., 1992; Warner et al., 1993a,b) .
Studies with broken cell systems show that ET-1 binds almost irreversibly to its receptors with a dissociation half-life in excess of 30 h (Waggoner et al., 1992) , which may explain the prolonged nature of its effects in vivo and in vitro (Yanagisawa et al., 1988; de Nucci et al., 1988) . Thus, receptor antagonists may act only weakly against established responses to ET-1. Here we have assessed the effectiveness of the endothelin receptor antagonists BQ-123 (ETA receptorselective, Ihara et al., 1992) and PD 145065 (ETA/ETB receptor non-selective, Cody et al., 1993; Doherty et al., 1993) in ' Author for correspondence.
reversing the in vivo pressor and in vitro vasoconstrictor effects of ET-1.
Some of these data have been presented to the British Pharmacological Society (Allcock et al., 1993; 1994) .
Methods
Rat blood pressure Male Wistar rats (250-400 g) were anaesthetized with sodium thiopentone (Intraval, 120 mg kg-', i.p.). The trachea was cannulated to facilitate respiration and body temperature was maintained at 37'C by means of a rectal probe connected to a homeothermic blanket (Biosciences, Sheerness, Kent). (Maggi et al., 1989; Warner et al., 1993a,b (3 x 10-'1 M) or methoxamine (2-2.5 x 10-5 M). Cumulative concentrations of BQ-123 (10-9 to 10-6 M) or PD 145065 (10-9 to 10-6 M) or vehicle were then infused into the kidney.
Changes in perfusion pressure were calculated when the responses to infusion reached a plateau level.
Materials
The Krebs buffer had the following composition (mM): NaCI 118, KCl 4.7, KH2PO4 1.2, MgSO4.7H20 1.17, CaC12.6H20 2.5, NaHCO3 25, glucose 5.6. The trifluoro- 
Statistics
Statistical differences between points were determined by an unpaired or paired two tail Student's t test, or repeated measures or one-way ANOVA with post hoc Bonferroni t test, as appropriate. A P < 0.05 was taken as significant. Statistical differences between curves were determined by two-way ANOVA and a P<0.01 taken as significant.
Results

Rat blood pressure
After the initial stabilisation period the MAP of the rats was 102± 1.5mmHg (n = 29) which fell to 93 ± 1.5 mmHg (n = 29, P <0.05, Student's t test) after treatment with hexamethonium.
Infusion of 60 min MAP was decreased by 11.8 ± 8.0 mmHg (n = 5) ( Figure 3b ). There was no significant change in the heart rate following infusion of PD 145065. Unlike BQ-123 (10-9 mol kg-' min-') infused alone, BQ-123 (10-9 mol kg-' min-') co-infused with PD 145065 (10-8molkg-'min-1) did not reduce the pressor effect of ET-1 (Figure 4a) . Similarly, BQ-123 (10-8mol kg-'min-') caused a smaller, although still significant (P<0.01, two-way ANOVA), reduction in MAP when infused with PD 145065 (108mol kg-' min-') than when infused alone (Figure 4b ). Co-infusion of BQ-123 and PD 145065 did not affect the heart rate.
In all experiments the MAP returned to that of vehicletreated animals within 60 min of ceasing BQ-123 and/or PD 145065 infusion (Figures 3a,b and 4a,b) .
Bolus injection of ET-1 (0.5 x 1010 mol kg-') caused a transient fall in blood pressure of 27 ± 6 mmHg (n = 4) followed by a prolonged pressor effect (maximum increase in MAP 42 ± 7 mmHg, n = 4). PD 145065 (0.5 x 10-7 and 0.5 x 10-6 mol kg-') dose-dependently inhibited the depressor effect of ET-1 (P <0.05, ANOVA) but did not significantly effect the secondary increase in MAP ( Figure 5 ).
Rat thoracic aorta
ET-1 (3 x 1O-9M) caused a sustained increase in tension (1.4 ± 0.1 g, n = 18) of the rings of rat aorta which was slowly reversed by additional application of or PD 145065 (10-5 M) (Figure 6a,b with BQ-123 (n = 6). Vehicle was without effect (n = 6, Figure 6a ,b). Phenylephrine (3 x 10-7 M) increased the tension of the rat aorta by 1.7 ± 0.1 g (n = 15). This constriction was unaffected by either BQ-123 (10-5M), PD 145065 (10-5M) or vehicle (n = 5 for each). 
Rat isolated perfused kidney
The basal perfusion pressure of the rat isolated kidney was 61.3 ± 2.9 mmHg (n = 24) which was increased by 138.1 ± 7.6 mmHg (n = 14) by infusion of ET-1 at 3 x 1010 M. Subsequent infusion of BQ-123 or PD 145065 (both 10-10 to a 10-6 M) reversed the vasoconstriction with thresholds of approximately 10-8 M (Figure 7 ). PD 145065 was significantly more active (P<0.01, two-way ANOVA), such that at 10-6 M it reduced the elevated perfusion pressure by 56.9 ± 8.8% (n = 5), whereas at the same concentration BQ-123 reduced it by 22.8 ± 8.0% (n = 4). Vehicle was without effect (n = 5, Figure 7 ).
Methoxamine (2-2.5 x 1i-0M) increased the perfusion pressure of the kidney by 159.3 ± 8.4 mmHg (n = 10) which was unaffected by BQ-123 (10-10 to 10-6 M, n = 3), PD 145065 (10-10 to 10-6M, n=3) or vehicle (n=4 (Maggi et al., 1988; Sumner et al., 1992) , are antagonized, by PD 145065 with a pA2 of 6.5 , and by BQ-123 with a pA2 of 6.9 (Sumner et al., 1992) . In (n = 4), (U). The ordinate scale represents the change in ET-linduced MAP starting from the infusion of antagonist. Results are calculated as the mean (± s.e.mean). The hatched bar represents presence of the ET-l infusion, and the solid bar the presence of antagonist/vehicle. In both panels the time axis is broken to separate the period of antagonist infusion (left side) from the period after antagonist was removed (right side). tions of the rat aorta induced by Similarly, in the rat isolated perfused kidney in which both ETA and ETB receptors mediate the vasoconstrictor effects of ET-1 (Cristol et al., 1993; Warner et al., 1993c) , as they do the pressor effects of ET-1 in vivo (Cristol et al., 1993; McMurdo et al., 1993) Possibly this difference is due to PD 145065 in vivo blocking the indirect vasodilator effects of ET-1, mediated by ETB receptors present on the endothelium (Warner et al., 1989; Takayanagi et al., 1991) and mediated by an increased production of nitric oxide and prostacyclin (de Nucci et al., 1988; Whittle et al., 1989) . This vasodilatation is revealed by a bolus injection of ET-1. In these experiments PD 145065 in doses 1000 or 10,000 greater than that of ET-l had no significant effect on the pressor response to ET-1, but did greatly diminish the initial fall in blood pressure. Conversely, BQ-123 and related compounds either do not affect the depressor effect of the endothelins or potentiate it (Ihara et al., 1992; McMurdo et al., 1993 (Sokolovsky et al., 1990) , and this site is contained within the structure of PD 145065.
BQ-123 (10-5 M)
Thus, PD145065 could inhibit ET-1 degradation by substrate competition. In all our experiments we saw reversal of the effects of ET-1 following administration of the antagonists in 100-10,000 excess, which may be explained by the very tight binding of ET-1 to its receptors (Hirata et al., 1988; Waggoner et al., 1992) . Indeed, in intact cells ET-1 appears only to become dissociated from its receptors following receptor internalisation with about 40% of receptors being recycled after 1 h. Thus, the slow reversal of the effects of ET-l caused by the antagonists may be a function of their ability to prevent new binding of ET-1 following re-externalization of the receptors (Marsault et al., 1993) . Interestingly, it suggests that the endothelin receptor antagonists should be administered in high doses for prolonged periods when testing their effectiveness in models of pathological ET-1 production (Kon et al., 1989; Watanabe et al., 1990) . Indeed, when administered as a bolus 10mgkg-' BQ-123 equivalent to 1.4 x 10-5 mol kg-', was needed to reduce the established pressor effects in conscious rats of an infusion of 10-11 mol kg-1 min-' ET-1 (Bazil et al., 1992) . The dose of antagonist used, therefore was equivalent to the amount of ET-1 that would be administered in a period of 32 months.
Thus, established vasoconstrictions induced by ET-1 and mediated via ETA and/or ETB receptors in vitro may be reversed slowly by the subsequent application of receptor antagonists. In vivo, the anti-pressor effects of a non-selective receptor antagonist may be limited by its ability to decrease the vasodilator effects of ET-1 and/or reduce the elimination of ET-1. In the rat, therefore, BQ-123, a selective ETA receptor antagonist, is more active than PD 145065, a nonselective ETA/ETB receptor antagonist, in reversing the established hypertensive effects of ET-1.
